Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Not Yet Opened 11-04 16:00:00 EST

5.19

-0.09

-1.70%

盘后5.44

+0.25+4.82%

19:51 EST

High5.44	Low5.18	Vol124.64K
Open5.26	D1 Closing5.28	Amplitude4.92%
Mkt Cap166.52M	Tradable Cap90.84M	Total Shares32.08M
T/O658.78K	T/O Rate0.71%	Tradable Shares17.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":5.19,"timestamp":1730754000000,"preClose":5.28,"halted":0,"volume":124644,"hourTrading":{"tag":"盘后","latestPrice":5.44,"preClose":5.19,"latestTime":"19:51 EST","volume":1381,"amount":7248.29,"timestamp":1730767894885},"delay":0,"floatShares":17503600,"shares":32084777,"eps":-1.709323,"marketStatus":"Not Yet Opened","change":-0.09,"latestTime":"11-04 16:00:00 EST","open":5.26,"high":5.44,"low":5.18,"amount":658776.0346908,"amplitude":0.049242,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.709323,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730797200000},"marketStatusCode":0,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":5.28,"preHourTrading":{"tag":"盘前","latestPrice":5.28,"preClose":5.28,"latestTime":"09:27 EST","volume":1002,"amount":5290.56,"timestamp":1730730434522},"postHourTrading":{"tag":"盘后","latestPrice":5.44,"preClose":5.19,"latestTime":"19:51 EST","volume":1381,"amount":7248.29,"timestamp":1730767894885},"volumeRatio":0.481251,"impliedVol":1.619,"impliedVolPercentile":0.7606},"requestUrl":"/m/hq/s/CADL/tweets","defaultTab":"tweets","newsList":[{"id":"2480283207","title":"Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think","url":"https://stock-news.laohu8.com/highlight/detail?id=2480283207","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480283207?lang=en_us&edition=fundamental","pubTime":"2024-11-02 00:40","pubTimestamp":1730479212,"startTime":"0","endTime":"0","summary":"Candel Therapeutics is working on intratumoral oncolytic virus therapy.A pair of mid to late-stage trials in prostate cancer are expected to read out in Q4.Positive findings could be the position of s","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352556232/image_1352556232.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352556232/image_1352556232.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4732099-candel-therapeutics-a-low-price-oncolytic-virus-play-further-along","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4539","BK4139","CADL"],"gpt_icon":0},{"id":"2479003304","title":"Candel Therapeutics Advances in Cancer Treatment Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2479003304","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479003304?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:59","pubTimestamp":1730206791,"startTime":"0","endTime":"0","summary":"An announcement from Candel Therapeutics  is now available.Candel Therapeutics has reported promising results from its ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma, showing improved survival rates for some patients. The trial data, presented at the International Oncolytic Virotherapy Conference, suggests CAN-3110 triggers immune system activation and tumor clearance. With its innovative viral immunotherapy approach, Candel is making strides in developing effective cancer treatments and expanding its clinical pipeline.See more insights into CADL stock on TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/candel-therapeutics-advances-cancer-treatment-125951149.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-advances-cancer-treatment-125951149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","CADL","BK4139","LENZ"],"gpt_icon":0},{"id":"2478104744","title":"Candel Therapeutics showcases cancer therapy candidates at IOVC","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478104744?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:11","pubTimestamp":1730117461,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference, taking place October 27...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-showcases-cancer-therapy-candidates-at-iovc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-showcases-cancer-therapy-candidates-at-iovc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CADL","BK4539","BK4139"],"gpt_icon":0},{"id":"2478104944","title":"Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104944","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478104944?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116800,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  28, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biolog","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/28/2970021/0/en/Candel-Therapeutics-Showcases-Innovative-Cancer-Therapy-Candidates-at-16th-Annual-International-Oncolytic-Virotherapy-Conference-IOVC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","CAN","BK4107","BK4170","BK4539","BK4080","BK4585","BK4097","BK4231","L","BK4588","SITC","TLS","BK4526","BK4595","LENZ","LU0053666078.USD"],"gpt_icon":0},{"id":"2472951184","title":"Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2472951184","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472951184?lang=en_us&edition=fundamental","pubTime":"2024-10-04 21:00","pubTimestamp":1728046800,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Oct.  04, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biolog","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/04/2958348/0/en/Candel-Therapeutics-to-Present-Preclinical-Data-on-Therapeutic-Potential-of-CAN-3110-in-Melanoma-at-SITC-2024-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","SITC","IE00BYQNZ168.SGD","LENZ","BK4170","BK4526","BK4539","BK4231","BK4595","CAN","BK4139","BK1103","IE00BYTNYN87.SGD","01308","CADL","BK1541","SG9999011746.SGD","IE00B12V2V27.USD"],"gpt_icon":0},{"id":"2467602883","title":"Retail investors who hold 48% of Candel Therapeutics, Inc. (NASDAQ:CADL) gained 14%, insiders profited as well","url":"https://stock-news.laohu8.com/highlight/detail?id=2467602883","media":"Simply Wall St.","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467602883?lang=en_us&edition=fundamental","pubTime":"2024-09-14 22:33","pubTimestamp":1726324400,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in Candel Therapeutics indicates that they collectively...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/retail-investors-who-hold-48-of-candel-therapeutics-inc-nasd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CADL","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","QLD","BK4112","QID","BK4539","PSQ","NQmain","SQQQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","MNQmain","BK4139","BK4588","TQQQ",".IXIC","NDAQ","BK4585"],"gpt_icon":1},{"id":"2467771626","title":"Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467771626","media":"Simply Wall St.","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467771626?lang=en_us&edition=fundamental","pubTime":"2024-09-13 22:15","pubTimestamp":1726236948,"startTime":"0","endTime":"0","summary":"The considerable ownership by individual investors in Candel Therapeutics indicates that they collectively have a greater say in management and business strategy. A total of 24 investors have a majority stake in the company with 50% ownership. To get a sense of who is truly in control of Candel Therapeutics, Inc. , it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 48% to be precise, is individual investors. In other words, the group stands to gain the most  from their investment into the company.And individual insiders on the other hand have a 30% ownership in the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders.Let's delve deeper into each type of owner of Candel Therapeutics, beginning with the chart below.While studying institutional ownership for a company can add value to your research, it is also a good prac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-inc-nasdaq-cadl-141548599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","IE00BGHQF748.EUR","PSQ","LU2210150020.SGD","MNQmain","BK4585","CADL","BK4112","QID","LU2095319765.USD","IE00B64PRP62.GBP","QLD","BK4539","BK4588","SQQQ","LU2210149790.SGD","NDAQ","NQmain","IE00B3QW5Z07.USD","BK4139","TQQQ","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2464720113","title":"BRIEF-Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa To Its Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2464720113","media":"Reuters","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464720113?lang=en_us&edition=fundamental","pubTime":"2024-09-04 20:50","pubTimestamp":1725454249,"startTime":"0","endTime":"0","summary":"Sept 4 (Reuters) - Candel Therapeutics Inc   :   * MILESTONE PHARMACEUTICALS APPOINTS INDUSTRY VETERAN JOSEPH PAPA TO ITS BOARD OF DIRECTORSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4007","MIST","BK4139","BK4583","BK4539"],"gpt_icon":1},{"id":"2464379383","title":"Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2464379383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464379383?lang=en_us&edition=fundamental","pubTime":"2024-09-04 20:00","pubTimestamp":1725451204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240904:nTUAN1MVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CADL","EBS","BK4539","BK4583","MIST","BK4007"],"gpt_icon":0},{"id":"2464487025","title":"Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2464487025","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464487025?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:00","pubTimestamp":1725364800,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Sept.  03, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biolo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/03/2939620/0/en/Candel-Therapeutics-to-Present-at-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CADL","LENZ"],"gpt_icon":0},{"id":"2459806131","title":"Candel Therapeutics Shares Rise After Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459806131","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459806131?lang=en_us&edition=fundamental","pubTime":"2024-08-14 01:46","pubTimestamp":1723571166,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["CADL","BK4139","BK4539"],"gpt_icon":0},{"id":"2459805901","title":"Candel Therapeutics Shares Rise After Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459805901","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459805901?lang=en_us&edition=fundamental","pubTime":"2024-08-14 01:46","pubTimestamp":1723571166,"startTime":"0","endTime":"0","summary":"Candel Therapeutics  shares rose nearly 3% in recent trading Tuesday after the company reported its Q2 results.Candel booked a diluted net loss of $0.74 per share, widening from a loss of $0.33 a year earlier.No comparable estimates were available on Capital IQ.As expected, no revenue for the quarter ended June 30 was reported.The company said it had $21.5 million in cash and cash equivalents, and expected it to fund operations through Q1 2025.Price: 5.74, Change: +0.16, Percent Change: +2.87","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","CADL","BK4539","BK4139"],"gpt_icon":0},{"id":"2459973901","title":"Candel Therapeutics GAAP EPS of -$0.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2459973901","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459973901?lang=en_us&edition=fundamental","pubTime":"2024-08-13 21:47","pubTimestamp":1723556869,"startTime":"0","endTime":"0","summary":"Candel Therapeutics press release  (NASDAQ:CADL): Q2  GAAP EPS of -$0.74.\nCash and cash equivalents, as of June 30, 2024, were $21.5 million, as compared to $35.4 million as of December 31, 2023.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4139157-candel-therapeutics-gaap-eps-of-0_74","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CADL","LENZ"],"gpt_icon":0},{"id":"2459281972","title":"Candel Therapeutics Q2 EPS $(0.74) Down From $(0.33) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2459281972","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459281972?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:05","pubTimestamp":1723550733,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.74) per share. This is a 124.24 percent decrease over losses of $(0.33) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40335704/candel-therapeutics-q2-eps-0-74-down-from-0-33-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CADL"],"gpt_icon":0},{"id":"2459697263","title":"BRIEF-Candel Therapeutics Q2 Net Income USD -22.237 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2459697263","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459697263?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:00","pubTimestamp":1723550449,"startTime":"0","endTime":"0","summary":"Aug 13 (Reuters) - Candel Therapeutics Q2 basic EPS USD -0.74. * Q2 income from operations USD -8.571 million * Q2 operating expenses USD 8.571 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","USD","LENZ","CADL"],"gpt_icon":0},{"id":"2459972112","title":"Candel Therapeutics Inc- Sees Existing Cash & Cash Equivalents Will Be Sufficient to Fund Current Operating Plan Into Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2459972112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459972112?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:00","pubTimestamp":1723550405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA2LGV44:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2459797218","title":"Candel Therapeutics  - on Track for Topline Disease-Free Survival Data From Phase 3 Randomized Controlled Clinical Trial of Can-2409","url":"https://stock-news.laohu8.com/highlight/detail?id=2459797218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459797218?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:00","pubTimestamp":1723550405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA2LGV44:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","CADL","BK4539","BK4139"],"gpt_icon":0},{"id":"2459724629","title":"Candel Therapeutics Q2 Income From Operations USD -8.571 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2459724629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459724629?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:00","pubTimestamp":1723550404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nPLX7DCF20:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["USD","LENZ","CADL","BK4139","BK4539"],"gpt_icon":0},{"id":"2459972100","title":"Candel Therapeutics Q2 Net Income USD -22.237 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2459972100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459972100?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:00","pubTimestamp":1723550404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nPLX7DCF20:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","USD","BK4539","LENZ"],"gpt_icon":0},{"id":"2459972648","title":"Press Release: Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2459972648","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459972648?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:00","pubTimestamp":1723550400,"startTime":"0","endTime":"0","summary":"-- Announced positive survival data from the phase 2 randomized controlled. clinical trial of CAN-2409 in borderline resectable pancreatic cancer. -- Presented positive topline overall survival data from the phase 2. clinical trial of CAN-2409 in non-small cell lung cancer  at 2024. -- Received orphan drug designation from the U.S. Food and Drug. Administration  for both CAN-2409 and CAN-3110, for the treatment of. pancreatic cancer and recurrent high-grade glioma , respectively. -- On track for topline disease-free survival data from the phase 3. randomized controlled clinical trial of CAN-2409 in localized. intermediate/high risk prostate cancer, expected in Q4 2024. -- On track for topline progression-free survival data from the phase 2b. randomized controlled clinical trial of CAN-2409 in the active. Dr. Tak continued, \"Our inclusion in the Russell 3000 Index also marks a significant milestone in Candel's growth and offers an opportunity to increase our recognition within the inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","BK4555","BK4595","TM","CADL","BK4139","03160","BK4588","BK4526","TLS","BK4097","BK4099","LENZ","CAN","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":-0.0571},{"period":"1month","weight":-0.2247},{"period":"3month","weight":-0.024},{"period":"6month","weight":-0.4146},{"period":"1year","weight":5.1395},{"period":"ytd","weight":2.5918}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.043859},{"month":2,"riseRate":0.333333,"avgChangeRate":0.030556},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.055034},{"month":4,"riseRate":0.333333,"avgChangeRate":1.040307},{"month":5,"riseRate":1,"avgChangeRate":0.162009},{"month":6,"riseRate":0,"avgChangeRate":-0.203173},{"month":7,"riseRate":0,"avgChangeRate":-0.076538},{"month":8,"riseRate":1,"avgChangeRate":0.111639},{"month":9,"riseRate":0.5,"avgChangeRate":0.008481},{"month":10,"riseRate":0.25,"avgChangeRate":-0.151533},{"month":11,"riseRate":0,"avgChangeRate":-0.044102},{"month":12,"riseRate":0.666667,"avgChangeRate":0.137611}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction